GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-02-22| R&D

Male Birth Control Drug Proves Successful in Mice Models

by Nai Ye Yeat
Share To

Scientists from Cornell University announced their experimental drug temporarily blocks sperm in mice and prevents pregnancies in preclinical trials. The researchers described their approach as a “game-changer” that could pave the way for a male contraceptive pill and could ultimately share the birth control burden among genders.

According to the finding published in Nature Communications, the contraceptive was 100 percent effective at preventing pregnancy for about 2 hours in mice models, with total fertility returning 24 hours later.

Related Article: Scientists Uncover More Evidence of CBD’s Effect on Epileptic Seizures in Children

The Inequality in Birth Control Responsibility

There are no other reliable methods for men to prevent their sperm from impregnating their partner except for using condoms during intercourse or receiving a vasectomy. Although some previous studies on experimental male contraceptives have also achieved impressive success rates, most of them impact sperm development, which means taking months for the contraceptive to be reliable and taking weeks to reverse its effect.

Meanwhile, women have been taking contraceptive pills since the 1960s. Despite its efficacy in birth control and improvement in women’s reproductive health, it is often criticized due to the common side effects from the synthetic hormones in the pill, including severe migraines, vomiting, depression, and anxiety. 

Leveraging Natural Infertility Causes to Create a Male Contraceptive

Sperm require a protein called soluble adenylyl cyclase (sAC) to move, and those who suffer from rare genetic mutations fail to produce sAC and, thus, are infertile. So, the scientists devised the idea to try an sAC-inhibiting drug as a male contraceptive. Once sperm are immobile, they lose the ability to travel up the vaginal tract to fertilize an egg.   

To confirm the efficacy of destructing sperm motility, the team assessed the movement of sperm collected from 17 male mice, eight of whom received the drug. In samples collected 2 hours after mice received the drug, only 6 percent of sperm were mobile on average compared with 30 percent in samples from control mice. The effect wore off after about 24 hours, which means the novel contraceptive is also rapidly reversible.

In addition, the researchers paired 52 male mice with females 30 minutes after giving the males the contraceptive drug. After 2 hours, each pair had mated, and no pregnancies occurred, indicating the contraceptive was 100 percent effective. Moreover, no noticeable side effects were noticed even when mice received three times the standard dose of a comparable compound continuously for 42 days.  

Currently, researchers are planning to refine the drug so that it lasts longer before moving on to clinical trials. The final goal would be creating a pill that men could take shortly before sex, allowing them to make day-to-day decisions about their fertility.  

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
The First Non-prescription Oral Contraceptive approved by FDA
2023-07-18
R&D
Could This Anti-Sperm Immunocontraception Work As a Novel Female Birth Control?
2021-08-24
GeneOnline’s Top Ten Headlines of the Year
2019-12-30
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top